文献速递慢性肾脏病肾小球疾病

Alport综合征中蛋白尿、eGFR下降与肾衰竭路径

Proteinuria, eGFR Decline, and the Pathway to Kidney Failure in Alport Syndrome
RSS 订阅 · PubMed · J Am Soc Nephrol · 2026-10-28

本文综述Alport综合征中蛋白尿和eGFR下降与肾衰竭的证据,聚焦肾小球足细胞功能障碍可部分逆转与足细胞丢失及肾小球硬化相关蛋白尿不可逆两种成分,指出试验终点框架需考虑基因型、性别、年龄、基线蛋白尿、基线eGFR、病程及非线性轨迹。

要点

  • 蛋白尿源于早期GBM通透性异常、足细胞足突融合、足细胞脱落及肾小球硬化。
  • eGFR下降是累积肾单位丢失的较晚读出指标,反映向肾衰竭进展。
  • 活检标志物当前主要用于靶点结合与通路修饰,与肾衰竭风险的定量关系尚不明确。

核心结论

  • Alport综合征临床试验终点选择需能反映疾病活动并预测有意义的临床获益,且试验规模和时长可行。
  • 蛋白尿和eGFR下降与肾衰竭相关,但蛋白尿包含可部分逆转的足细胞功能障碍成分与较难逆转的足细胞丢失及肾小球硬化成分。
  • 终框架应纳入基因型、性别、年龄、基线蛋白尿、基线eGFR、病程及蛋白尿和eGFR下降的预期非线性轨迹。

研究设计与样本

  • 综述,检索范围未在摘要中明确报告。

主要发现

  • 肾脏中α3α4α5网络产生、组装或定位受损导致GBM组成异常、足细胞功能障碍、蛋白尿、肾小球硬化、滤过能力进行性丧失及肾衰竭。
  • 蛋白尿各成分相对贡献可能随基因型、性别、年龄和病程变化。
  • 活检标志物包括胶原α3α4α5(IV)定位、GBM超微结构、足细胞足突宽度、肾小球硬化和肾小管间质纤维化,可提供疾病通路分期信息。

临床怎么用

  • 临床试验终点设计应考虑蛋白尿和eGFR下降的非线性轨迹及基线蛋白尿、基线eGFR等协变量。
  • 活检标志物当前最适用于评估靶点结合和通路修饰,不宜单独作为肾衰竭替代终点。

局限性

  • 活检标志物变化与肾衰竭风险之间的定量关系尚不完全明确。
  • 蛋白尿中可逆与不可逆成分的相对贡献随基因型、性别、年龄和病程变化,难以统一量化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

J Am Soc Nephrol . 2026 Oct 28. doi: 10.1681/ASN.0000001318. Online ahead of print. ABSTRACT Alport syndrome is a genetic disorder caused by pathogenic variants in COL4A3, COL4A4, or COL4A5, which encode the α3, α4, and α5 chains of type IV collagen. These chains form the collagen α3α4α5(IV) network required for basement membrane function in the kidney, inner ear, and eye. In the kidney, impaired production, assembly, or localization of the α3α4α5 network leads to abnormal glomerular basement membrane (GBM) composition, podocyte dysfunction, proteinuria, glomerulosclerosis, progressive loss of filtration capacity, and kidney failure. End point selection for clinical trials in Alport syndrome requires measures that report disease activity and predict meaningful clinical benefit in trials of feasible size and duration. Proteinuria arises from early stages of Alport pathogenesis: abnormal GBM permeability, podocyte foot-process effacement, podocyte detachment, and glomerulosclerosis. eGFR decline is a later readout of cumulative nephron loss and progression toward kidney failure. This review examines the evidence linking proteinuria and eGFR decline to kidney failure in Alport syndrome, focusing on two contributors to proteinuria: 1) podocyte dysfunction with foot-process effacement, which may be partially modifiable, and 2) proteinuria associated with podocyte loss and glomerulosclerosis, which is less likely to be reversible. The relative contribution of these components may vary with genotype, sex, age, and disease duration. Biopsy-based markers, such as collagen α3α4α5(IV) localization, GBM ultrastructure, podocyte foot-process width, glomerulosclerosis, and tubulointerstitial fibrosis, provide staging information along the disease pathway. The current role of these biopsy markers is strongest for target engagement and pathway modification, because quantitative relationships between changes in these markers and kidney failure risk remain incompletely defined. An end point framework for Alport syndrome should account for genotype, sex, age, baseline proteinuria, baseline eGFR, disease duration, and the expected nonlinear trajectories of proteinuria and eGFR decline. PMID: 42949772 | DOI: 10.1681/ASN.0000001318

来源:PubMed · J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. PubMed · J Am Soc Nephrol:Proteinuria, eGFR Decline, and the Pathway to Kidney Failure in Alport Syndrome

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。